Global Bispecific Antibody Therapeutics Contract Manufacturing Market is valued at approximately USD 5.29 billion in 2022 and is anticipated to grow with a healthy growth rate of more than 36.4% over the forecast period 2023-2030. Bispecific antibody therapeutics contract manufacturing refers to the outsourcing of the manufacturing processes involved in producing bispecific antibodies to specialized contract manufacturing organizations (CMOs). Bispecific antibodies are a group of therapeutic molecules created to concurrently target two distinct antigens, which are often located on the surface of cells implicated in illnesses including cancer, autoimmune disorders, and infectious diseases. These antibodies have huge potential due to their capacity to increase therapy specificity and effectiveness. The rise in incidences of chronic diseases such as cancer and autoimmune disorders, surging demand for personalized medicine, as well as globalization of the biopharmaceutical industry are the key factors that are spurring the market demand across the globe.
In addition, a robust pipeline of bispecific antibody therapeutics is witnessing a positive impact on the market growth in the global market. Biopharmaceutical companies often outsource manufacturing to dedicated contract manufacturers to accelerate development timelines in various stages of development. According to BioPharm International, the versatility of bispecific antibody therapeutics extends across various clinical domains such as tumor immunotherapy, neurological disorders, targeted drug delivery, and infectious diseases. As per the BioPharm International, bispecific antibody therapeutics ideally have broad clinical applications in tumor immunotherapy, targeted drug delivery, neurological disorders, or infective diseases. Also, the surge in enthusiasm for bispecific antibody research, coupled with heightened investments in immunotherapy, novel clinical trials, and regulatory approvals is resulting in market expansion. According to the results of the phase I/II clinical trial, individuals with refractory or relapsed multiple myeloma witnessed a 90.5% response rate to the bispecific antibody REGN5459. The outcomes of the bispecific antibody studies in humans were also reported at the annual meeting of the American Association for Cancer Research in 2023. The U.S. FDA has approved the first bispecific antibody targeting BCMA & CD3 for patients with persistent multiple myeloma as a result of the REGN5459 new results. Similarly, according to Sino Biological, Catumaxomab, the first licensed bispecific antibody (bsAB), was among the six bsABs for cancer immunotherapy that the EMA and/or FDA approved as of 2022. Thus, these aforementioned factors are propelling the growth of the bispecific antibody therapeutics Contract Manufacturing Market during the estimated period. Moreover, the ongoing research activities in bispecific antibody therapeutics, as well as technological advancements in biotechnology present various lucrative opportunities over the forecast years. However, the regulatory challenges and the high cost associated with the manufacturing of bispecific antibodies are hampering the market growth throughout the forecast period of 2023-2030.
The key regions considered for the Global Bispecific Antibody Therapeutics Contract Manufacturing Market study include Asia Pacific, North America, Europe, Latin America, and Middle East & Africa. North America dominated the market in 2022 owing to the high cost of drug development, rising number of clinical trials, technological advancements in biotechnology, and growing research activities. Whereas, Asia Pacific is expected to grow at the highest CAGR over the forecast years. The increase in demand for bispecific antibodies, rising demand for personalized medicine, coupled with the growing prevalence of cancer and the need for new medications in major countries including China, India, and Japan. are significantly propelling the market demand across the region.
Major market players included in this report are:
Lonza Group AG
F. Hoffmann-La Roche Ltd
Creative Biolabs Inc.
Janssen Global Services, LLC
Johnson & Johnson Services, Inc
IQVIA Holdings Inc.
WuXi Biologics Holdings Co. Ltd.
Sino Biological Inc.
Recent Developments in the Market:
Ø In June 2022, The European Commission issued a conditional marketing authorization for the Roche company’s CD20xCD3 T-cell binding bsAB Lunsumio (mosunetuzumab). It is used to treat follicular lymphoma that has relapsed or is resistant among individuals who have already had two systemic therapies.
Global Bispecific Antibody Therapeutics Contract Manufacturing Market Report Scope:
ü Historical Data – 2020 – 2021
ü Base Year for Estimation – 2022
ü Forecast period – 2023-2030
ü Report Coverage – Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
ü Segments Covered – Indication, Route of Administration, End-use, Region
ü Regional Scope – North America; Europe; Asia Pacific; Latin America; Middle East & Africa
ü Customization Scope – Free report customization (equivalent up to 8 analyst’s working hours) with purchase. Addition or alteration to country, regional & segment scope*
The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.
The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:
Autoinflammatory and autoimmune diseases
By Route of Administration:
Middle East & Africa
Rest of Middle East & Africa